Immunocore Holdings PLC reports results for the quarter ended December 31 - Earnings Summary
26/02/2025 14:31
Immunocore Holdings PLC IMCR.OQ reported a quarterly adjusted loss of 47 cents per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of sixteen analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -93 cents to 7 cents per share. Revenue rose 19.8% to $84.05 million from a year ago; analysts expected $85.91 million. Immunocore Holdings PLC's reported EPS for the quarter was a loss of 47 cents. The company reported a quarterly loss of $23.77 million. Immunocore Holdings PLC shares had fallen by 1.0% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 3.2% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Immunocore Holdings PLC is $67.00 This summary was machine generated from LSEG data February 26 at 02:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.26 | -0.47 | Missed |
| Sep. 30 2024 | -0.35 | 0.17 | Beat |
| Jun. 30 2024 | -0.48 | -0.23 | Beat |
| Mar. 31 2024 | -0.36 | -0.49 | Missed |